DaVita 将来の成長

Future 基準チェック /06

DaVitaは、4.3%と3.5%でそれぞれ年率4.3%で利益と収益が成長すると予測される一方、EPSはgrowで11.8%年率。

主要情報

4.3%

収益成長率

11.8%

EPS成長率

Healthcare 収益成長	25.9%
収益成長率	3.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	06 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

BMV:DVA * - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	13,698	889	1,387	2,224	7
12/31/2025	13,226	848	1,144	1,987	8
12/31/2024	12,754	836	870	1,806	8
9/30/2024	12,667	828	1,416	1,960	N/A
6/30/2024	12,524	860	1,269	1,810	N/A
3/31/2024	12,338	816	920	1,462	N/A
12/31/2023	12,140	692	1,491	2,059	N/A
9/30/2023	11,911	596	1,314	1,918	N/A
6/30/2023	11,739	454	1,357	1,967	N/A
3/31/2023	11,665	500	1,077	1,705	N/A
12/31/2022	11,610	547	961	1,565	N/A
9/30/2022	11,637	680	1,152	1,751	N/A
6/30/2022	11,627	834	995	1,607	N/A
3/31/2022	11,616	903	1,479	2,099	N/A
12/31/2021	11,619	978	1,289	1,931	N/A
9/30/2021	11,580	984	1,209	1,886	N/A
6/30/2021	11,566	883	1,124	1,802	N/A
3/31/2021	11,529	791	1,108	1,773	N/A
12/31/2020	11,551	783	1,304	1,979	N/A
9/30/2020	11,544	832	1,506	2,175	N/A
6/30/2020	11,524	824	1,648	2,333	N/A
3/31/2020	11,487	816	2,112	2,834	N/A
12/31/2019	11,388	705	1,730	2,496	N/A
9/30/2019	11,311	623	1,406	2,235	N/A
6/30/2019	11,253	548	1,124	2,011	N/A
3/31/2019	11,300	551	255	1,208	N/A
12/31/2018	11,412	616	544	1,531	N/A
9/30/2018	11,378	617	621	1,592	N/A
6/30/2018	11,299	698	N/A	1,679	N/A
3/31/2018	11,110	652	N/A	1,470	N/A
12/31/2017	10,884	909	N/A	1,966	N/A
9/30/2017	7,773	1,065	N/A	1,983	N/A
6/30/2017	8,732	1,480	N/A	2,016	N/A
3/31/2017	9,747	1,382	N/A	2,391	N/A
12/31/2016	10,696	1,038	N/A	1,988	N/A
9/30/2016	14,550	716	N/A	1,918	N/A
6/30/2016	14,347	361	N/A	2,061	N/A
3/31/2016	14,065	478	N/A	1,576	N/A
12/31/2015	9,973	323	N/A	1,531	N/A
9/30/2015	13,565	484	N/A	1,051	N/A
6/30/2015	13,290	452	N/A	1,219	N/A
3/31/2015	13,027	429	N/A	1,450	N/A
12/31/2014	12,781	723	N/A	1,459	N/A
9/30/2014	12,519	727	N/A	1,884	N/A
6/30/2014	12,270	680	N/A	1,769	N/A
3/31/2014	11,971	787	N/A	1,813	N/A
12/31/2013	11,759	620	N/A	1,773	N/A

アナリストによる今後の成長予測

収入対貯蓄率: DVA *の予測収益成長率 (年間4.3% ) は貯蓄率 ( 8.1% ) を下回っています。

収益対市場: DVA *の収益 ( 4.3% ) MX市場 ( 11.4% ) よりも低い成長が予測されています。

高成長収益: DVA *の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: DVA *の収益 ( 3.5% ) MX市場 ( 7.2% ) よりも低い成長が予測されています。

高い収益成長: DVA *の収益 ( 3.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: DVA *の自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

DaVita 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Third quarter 2024 earnings released: EPS: US$2.56 (vs US$2.70 in 3Q 2023)

DaVita Appoints Jessica Hergenreter as Chief People Officer

DaVita Inc. to Report Q3, 2024 Results on Oct 29, 2024

DaVita Announces Executive Appointments, Effective September 15, 2024

DaVita Inc. to Report Q2, 2024 Results on Aug 06, 2024

High number of new directors

Independent Director recently sold Mex$12m worth of stock

DaVita Appoints Madhu Narasimhan as Chief Information Officer, Effective June 3, 2024

High number of new directors

DaVita Inc., Annual General Meeting, Jun 06, 2024

DaVita Inc. to Report Q1, 2024 Results on May 02, 2024

Davita Announces Dennis Pullin to Its Board of Directors

DaVita Inc. to Report Q4, 2023 Results on Feb 13, 2024

DaVita Inc. to Report Q3, 2023 Results on Nov 07, 2023

DaVita Inc. Announces Management Changes

DaVita Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chief Legal & Public Affairs Officer recently sold Mex$18m worth of stock

First quarter 2023 earnings released: EPS: US$1.28 (vs US$1.68 in 1Q 2022)

DaVita Inc. to Report Q4, 2022 Results on Feb 22, 2023

Independent Director recently bought Mex$7.0m worth of stock

Third quarter 2022 earnings released: EPS: US$1.16 (vs US$2.48 in 3Q 2021)

DaVita Inc. to Report Q3, 2022 Results on Oct 28, 2022

DaVita Inc. Appoints Adam H. Schechter to Board of Directors

DaVita Inc. to Report Q2, 2022 Results on Aug 01, 2022

Chief Operating Officer of Kidney Care recently bought Mex$31m worth of stock

Independent Director recently sold Mex$4.4m worth of stock

DaVita Inc., Annual General Meeting, Jun 09, 2022

DaVita Inc. to Report Q1, 2022 Results on May 05, 2022

DaVita Inc. Appoints Jason M. Hollar as Independent Director

Independent Director recently sold Mex$1.6m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

DaVita Inc. (NYSE:DVA) acquired 17 Dialysis Centers in United States.

DaVita Inc. to Report Q4, 2021 Results on Feb 10, 2022

DaVita Inc. (NYSE:DVA) acquired MedSleuth, Inc.

Third quarter 2021 earnings released: EPS US$2.48 (vs US$1.31 in 3Q 2020)

Second quarter 2021 earnings released: EPS US$2.76 (vs US$1.65 in 2Q 2020)

CFO & Treasurer recently sold Mex$99m worth of stock

DaVita Inc. (NYSE:DVA) acquired a Dialysis Center in US.

Davita's China Affiliate to Invest in Hunan Fangsheng Pharma's Unit for 31.7% Stake

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS US$6.54 (vs US$4.61 in FY 2019)

Revenue misses expectations

Kyros Law Files Legal Claims on Behalf of Davita Inc Investors

DaVita Inc. to Report Q4, 2020 Results on Feb 11, 2021

Renalytix AI plc and DaVita Announce Partnership

DaVita Inc. Announces Management Changes, with Effect from December 15, 2020

Chief Operating Officer of Kidney Care recently sold Mex$55m worth of stock

Chief Legal Officer recently sold Mex$21m worth of stock

Market bids up stock over the past week

DaVita Inc. to Report Q3, 2020 Results on Oct 29, 2020

DaVita Inc. Announces the Retirement of Leanne M. Zumwalt, Group Vice President, Government Affairs

Independent Director recently bought Mex$10m worth of stock

An unknown buyer acquired RMS Lifeline, Inc. from DaVita Inc. (NYSE:DVA).

DaVita Inc. to Report Q2, 2020 Results on Jul 30, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘